Armata’s AP-SA02 Receives FDA Breakthrough Designation
Los Angeles, California, U.S., September 14, 2026 Armata Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has...
Phase 3 trial
Advertisement
Novo Nordisk Reports Positive STEP Young Phase 3 Data
Bagsværd, Denmark — September 7, 2026 Novo Nordisk announced positive first results from the STEP Young Phase 3 trial,...
Inventiva Completes Phase 3 NATiV3 Trial of Lanifibranor in MASH
Daix, France and New York, September 2, 2026 Inventiva announced that the last patient has completed the final 72-week...
Immuneering Advances Atebimetinib in Pancreatic Cancer
NEW YORK – August 26, 2026 Immuneering Corporation (Nasdaq: IMRX) highlighted its continued focus on first-line metastatic pancreatic cancer...
Bridge to Life Raises $110M to Expand Organ Perfusion
DULUTH, Georgia, August 12, 2026 Bridge to Life Ltd., a medical technology company specializing in organ preservation and perfusion...
Advertisements
Eli Lilly Escalates Fight Against Illegal Retatrutide Market
INDIANAPOLIS, Indiana, August 12, 2026 Eli Lilly and Company has intensified its efforts to combat the illegal sale of...
Entera Bio Advances EB613 Toward Phase 3 Development Following FDA Alignment
TEL AVIV, August 7, 2026 Entera Bio reported its second quarter 2026 financial results and business updates, highlighting regulatory...
aTyr Pharma Prioritizes Efzofitimod as FDA Phase 3 Feedback Approaches
SAN DIEGO, August 7, 2026 aTyr Pharma reported its second quarter 2026 results and announced a corporate restructuring designed...
Amylyx Pharmaceuticals Advances Avexitide Toward Phase 3 Data
CAMBRIDGE, Mass., August 6, 2026 Amylyx Pharmaceuticals reported its second quarter 2026 financial results, highlighting significant progress across its...
X4 Pharmaceuticals Reports Q2 2026 Results and Advances Mavorixafor Development
BOSTON, August 6, 2026 X4 Pharmaceuticals reported second quarter 2026 financial results while highlighting continued progress in the global...
Advertisement
